Drug intelligence / Profile preview

YZ-0209

Development stage: Preclinical
Lead developer: Guangdong Yinzhu Pharmaceutical Technology
Modality: Small Molecules

Overview

YZ-0209 is a preclinical **small-molecule fixed-dose combination** being developed by Guangdong Yinzhu Pharmaceutical Technology for **ALK-positive non-small cell lung cancer**. The program is listed in the company's combination-formulation development platform and is associated with nuclear factor kappa B signaling; the individual active ingredients, exact formulation, route of administration, and precise molecular pharmacology have not been publicly disclosed. ([yinzhupharma.com](https://www.yinzhupharma.com/list/20.html))

Targets

NF-κB

Beyond the preview

Go deeper on YZ-0209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YZ-0209.

Explore the full profile